Robert Sully

AMCo (Formerly Amdipharm Mercury Ltd)

AMCo is a rapidly-growing international pharmaceutical company. We supply niche medicines that make a real difference to the patients, doctors, hospitals and healthcare authorities we serve in over 100 countries worldwide. We are building our portfolio of global niche medicines through acquisition, in-licensing and internal developments. AMCo is the result of a merger of Amdipharm and the Mercury Pharma Group in 2013. We have since acquired a number of other pharma companies and medicines. Our most recent company acquisitions are the Focus Group, based in the UK, and Abcur AB, based in Sweden. Our most recent product acquisition is Fucithalmic® which we acquired from LEO Pharma in 2013. This growth allows us to offer a wide-ranging portfolio of niche prescription-only medicines to patients, with opportunities for more being available in the future. We have a well-established, international distribution network and a proven track record in sales and marketing of prescription medicines with strong technical and regulatory support. Our small, focused teams have local knowledge of the regions in which they live and work, supporting effective local healthcare solutions. This has led to an increase in sales in the 112 countries in which we now operate. AMCo are part of the highly effective generics industry in the UK which is estimated to save the UK's NHS almost £9 billion pounds in healthcare costs each year (source: British Generic Manufacturers Association) .